相关实验视频
Updated: Jul 15, 2025
12:43
On-Chip Endothelial Inflammatory Phenotyping
Published on: July 21, 2012
11.0K
与心血管疾病和心脏代谢风险因素相关的TNF抑制剂:孟德尔的随机化研究
1Department of Cardiology, Anhui Provincial Children's Hospital, Hefei, Anhui, China. xxzs312@163.com.
European review for medical and pharmacological sciences
|October 2, 2023
概括
基因代理瘤坏死因子 (TNF) 抑制显示了对心血管健康的潜在益处. 这项研究将TNF抑制与降低高血压,冠状动脉疾病和2型糖尿病的风险联系起来.
科学领域:
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于抗瘤亡因子 (TNF) 疗法对心血管的影响存在分歧.
- 瘤亡因子受体1 (TNFR1) 和TNF在与心血管疾病 (CVD) 相关的炎症过程中发挥作用.
研究的目的:
- 研究长期瘤亡因子 (TNF) 抑制对心血管疾病 (CVD) 和心脏代谢风险因素的因果关系.
- 使用门德尔随机化 (MR) 来评估TNF及其受体TNFR1.1的基因代理抑制.
主要方法:
- 采用两样本的门德尔随机化 (MR),使用基因仪器进行TNF抑制.
- 在TNFRSF1A和TNF基因附近利用单核酸多态 (SNPs) 和表达量化特征位点 (eQTLs).
- 应用逆方差加权MR (IVW-MR) 和基于总结的MR (SMR) 来估计因果关系.
主要成果:
- 基因代理的TNF抑制与降低高血压,冠状动脉疾病,冠状动脉样硬化和2型糖尿病的风险显著相关.
- 这些发现在FinnGen研究中得到了验证.
- 此外,TNF抑制还与脂质谱,血压和体重指数的有利变化有关.
结论:
- 基因代理的TNF抑制与几种心血管疾病的减少有因果关系.
- 这表明TNF抑制在控制心脏代谢风险因素方面具有潜在的保护作用.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
01:27Psychoneuroimmunology: Cardiovascular Disease
46
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
46
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
01:21Rheumatic Heart Disease III: Medical Management
11
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
11
01:30Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11